Elyar J S, Tellier M C, Soos J M, Yamamoto J K
Department of Pathobiology, College of Veterinary Medicine, University of Florida, Gainesville 32610, USA.
Vaccine. 1997 Aug-Sep;15(12-13):1437-44. doi: 10.1016/s0264-410x(97)00056-x.
Feline immunodeficiency virus (FIV), discovered a decade ago, is the causative agent of feline immunodeficiency syndrome (FAIDS), a chronically degenerative, fatal disease in domestic cats. Our understanding of the immunopathogenesis of FIV has improved but the development of an effective therapy and prophylaxis has been slow, reflecting the remarkable adaptability of the virus to modern medical intervention. FIV vaccine development has had its successes and failures similar to those encountered in human immunodeficiency virus (HIV) vaccine research. This review summarizes the status of FIV vaccine research, including trials of conventional, recombinant subunit and recombinant vector-based vaccines, and potential mechanisms of vaccine protection. The lessons learned from the FIV model should provide new insights for the approaches toward the development of HIV vaccines.
